Advancing Multiple Shots On Clinical Goals, Coeptis Therapeutics Positions For A Busy Value-Creating 2H/2023 ($COEP)

June 06 05:06 2023
Advancing Multiple Shots On Clinical Goals, Coeptis Therapeutics Positions For A Busy Value-Creating 2H/2023 ($COEP)

Coeptis Therapeutics (NasdaqGM: COEP) has been gaining recognition among investors and is steadily making its way into investment portfolios. There are several excellent reasons justifying the bullish trend. Foremost is that COEP is helping to pioneer potentially ground-breaking cell therapy and cancer treatment platforms, which has helped support a steepening of its share price curve, ending May over 59% higher and scoring levels during the month not seen since November 2022.

Here’s even better news: more than just retail and institutional investors are paying attention to the COEP story. Coeptis recently announced that its SNAP-CAR technology was featured in a peer-reviewed article in Nature Communications. SNAP-CAR is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications. Notably, the article highlighted where being different can be an advantage, specifically the advances in antigen receptor design related to developing “universal” receptor systems using covalent chemistry. Evidence is accumulating that these systems show the potential for clinical application and biotechnological utility, which could facilitate allowing researchers to screen CAR and synNotch antibody candidates and activate cellular programs in response to specific antibody-antigen interactions.

That’s a big deal. And the totality of the COEP pipeline, particularly the inherent value in play, supports the case that while May posted an impressive and bullish run for the stock, the best may be yet to come.

Validation In Peer-Reviewed Nature Communications

That’s a relatively easy case to make. Noting the synergies of its various initiatives, the current COEP share price, despite its May jump, still does not appropriately appraise the combined intrinsic value within a strengthening asset portfolio. Moreover, it fails to reflect the value inherent to partnerships, working research relationships, and IP assets that, even if taken singularly, are likely worth more than its recent $1.90 stock price.

Keep in mind that the peer-reviewed publication is a validating feature for COEP, as earning a spot in a highly regarded journal is no easy task. The people reviewing, testing, authenticating, and evaluating the methods used to make assumptions and conclusions are critically tested and only signed off on once they are confident that their reviews will not damage the years taken to establish a reputation as a critical and challenging thinker. Thus, the coverage in Nature Communications should be recognized for what it is: a valuable milestone that can expedite COEP’s work to reach catalyst impact. The particulars are what matters.

In its review, researchers showcased the creation of universal adaptor synNotch and CAR systems, which enable programmable antigen targeting. Moreover, it’s a breakthrough showing that one population of T cells has the potential to target multiple tumor antigens, an important distinction that paves the way for cell therapies across a wide range of cancers. Ongoing research has COEP advancing science in a particularly hot sector, targeting HER2-expressing cancer as its potential first-in-human clinical development program, emphasizing the power of SNAP-CAR technology. While it’s a significant shot at a revenue-generating goal, particularly through potential licensing and/or partnership opportunities, there’s still more supporting the COEP investment proposition.

Partnerships And Working Relationships

In April, COEP announced a binding term sheet with Deverra Therapeutics, Inc. for acquiring or licensing assets related to Deverra’s allogeneic stem cell expansion and directed differentiation platform. This platform aims to generate multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. From a value-creating perspective, closing the transaction would provide COEP with exclusive rights to FDA-approved Investigational New Drug (IND) applications and Phase 1 clinical trials investigating DVX201, an unmodified NK cell therapy, in hematologic malignancies and viral infections. It would also grant access to a highly scalable allogeneic cellular immunotherapy platform, offering off-the-shelf, cost-effective cell therapies for a broad patient population. The completion of Deverra’s AML study’s Phase I clinical trial data is expected in the second half of 2023.

Expanding clinical interests also contribute to COEP’s bullish thesis. The finalized transaction with Deverra would significantly enhance Coeptis’ technology portfolio, incorporating a cutting-edge allogeneic cell therapy platform with extensive safety and clinical data. This expansion aligns COEP’s development ambitions with leading cell and gene therapy experts, diversifying its R&D capabilities and strengthening its clinical pipeline assets. The allogeneic cell therapy platform offers possibilities to expand COEP’s cell-based therapies beyond autologous CAR T, generating allogeneic NK and MAC cell therapies by combining Deverra’s immune effector cell generation and COEP’s target-specific CARs. The best part of this potential value driver is that it’s likely a near-term contributor. And there are others.

COEP’s partnerships with other companies, including VyGen-Bio and the University of Pittsburgh, add further milestones to its development programs. These collaborations focus on improving the treatment of CD38-related cancers, licensing a multi-antigen CAR T technology (SNAP-CAR), and developing the GEAR™ cell therapy and companion diagnostic platforms. By maximizing the value of its product portfolio through in-license agreements, out-license agreements, and strategic partnerships, COEP aims to bring better therapeutics to market and create significant shareholder value.

A Value Proposition That Is Getting Tighter

Considering everything happening, there’s a clear deduction: take advantage of a valuation gap between assets, partnerships, and a growing stable of research relationships sooner than later. Indeed, the spike in May indicates many investors already are, which could cause an open window of value opportunity to close quickly. For those tuning in, that shouldn’t be unexpected.

Coeptis Therapeutics’ cell and gene therapies have the potential to disrupt current treatment paradigms, making it an attractive target for larger pharmaceutical companies seeking early-stage development assets. Remember, Big Pharma companies like Johnson & Johnson (NYSE: JNJ), Pfizer (NYSE: PFE), and Bristol Myers Squibb (NYSE: BMY) have made it part of their strategies to acquire promising assets rather than develop them from pre-clinical stages. In other words, with multiple shots on goal and having unique features to its assets, COEP could be in play.

And with analysts forecasting COEP shares to reach $5.00 per share and providing evidence to justify the bullish sentiment, Coeptis Therapeutics may present an exceptionally compelling proposition at current prices.



Disclaimers: Shore Thing Media, LLC. (STM, Llc.) is responsible for the production and distribution of this content. STM, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by STM, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall STM, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by STM, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. STM, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, STM, Llc., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. STM, LLC has been compensated up to five-thousand-dollars cash via wire transfer by a third party to produce and syndicate content for Coeptis Therapeutics, Inc. for a period of two weeks ending on May 11, 2023. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: STM, LLC.
Contact Person: Michael Thomas
Email: [email protected]
Phone: 917-773-0072
Country: United States

view more articles

About Article Author